Science
MRI-based microparticle sensor measures pressure inside tumors in real time Gradual pressure activates cell-protective pathways, while sudden changes promote metastasis

A U.S.-Korea research team used a magnetic resonance imaging (MRI)-based sensor to show that sudden changes in tissue pressure trigger cancer cell metastasis.
Researchers from the Center for Nanomedicine at the Institute for Basic Science (IBS) in South Korea and the University of California, San Francisco (UCSF) published the findings Sept. 28 in the journal Nature Nanotechnology.
The researchers developed a microparticle sensor called “mechanoMR.” The sensor is an MRI-responsive hydrogel microparticle containing iron oxide nanoparticles that converts mechanical pressure on tissue into a quantitative MRI signal at the single-particle level.
When pressure compresses the hydrogel, the amount of water inside decreases and the diffusion of protons around the nanoparticles is restricted, changing the MRI signal. The researchers calibrated this signal to enable quantitative measurement of tissue pressure in the range of 0–15 kPa.
The researchers applied the sensor to tumor spheroids and mouse transplant models to noninvasively monitor changes in tissue pressure in real time as tumors grew. They found a distinctive pattern of pressure remodeling during epithelial-mesenchymal transition (EMT).
In particular, sudden pressure spikes—not cumulative or peak pressure—emerged as the decisive factor triggering EMT. Transcriptome analysis showed that gradual pressure loading activated the FOXO/AMPK pathway, which protects cells, and increased the stability of epithelial cells.
By contrast, the researchers concluded, sudden pressure spikes disrupted this defense mechanism and prompted cells to reprogram into a mesenchymal state.
The researchers said they expect the findings to support the use of the sensor as a versatile platform linking tissue mechanics with changes in cell state during development and disease.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
Blocking Disease Proteins With ‘Molecular Gates’ … Gate Bioscience Prepares to Enter the Clinic

Rezolute Meets Phase 3 Goal in Tumor Hyperinsulinism, Shares Rise Ahead of FDA Meeting

Regeneron’s POTS drug succeeds in Phase 2; Phase 3 to begin in first half of next year

Egene Receives Approval to Amend Phase 2/3 Trial of Quadrivalent Meningococcal Vaccine

GC Biopharma Develops Korea’s First Generative AI Drug Safety Monitoring Software, Focused on Preventing Missed Cases

Daewoong Pharmaceutical Wins Phase 1 Approval for Drug to Regenerate Intestinal Mucosa: “Beyond Immunosuppression”